U.S. Markets open in 1 hr 47 mins

Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

NASDAQ, TSX: NVCN

VANCOUVER , July 9, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN) (NVCN.TO), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will request a hearing before the Nasdaq Hearings Panel (the "Panel") as the next step in the process to seeking an additional 180-day extension for compliance with the US$1 minimum bid price requirement.  On July 6, 2018 , the Company received the expected notice from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Staff has determined to delist the Company's common shares from Nasdaq Capital Market unless the Company requests a hearing before the Panel by July 13, 2018 , which the Company will do.

As previously announced, the Company has already received shareholder approval to execute a reverse stock split, common share consolidation, to enable the Company to regain compliance with the minimum bid price requirement.  However, the Company is seeking an additional 180-day extension so that the Board and management can effect the reverse stock split at a time, during that extension, if granted, that is in the best interest of the Company and its stakeholders.

On January 2, 2018 , the Staff notified the Company that it did not comply with the US$1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The Company was provided an initial compliance period of 180 days, or until July 2, 2018 , to regain compliance with Listing Rule 5550(a)(2). On July 6, 2018 , the Company received the expected notice from the Staff indicating that the Staff has determined to delist the Company's common shares from the Nasdaq Capital Market.

As previously disclosed, the Company will request a hearing before the Panel, at which it will request an additional 180-day extension and present its plan for regaining compliance with the minimum bid price requirement. This request will ordinarily automatically stay any delisting or suspension action pending the issuance of a final decision by the Panel; however, the Nasdaq has broad discretionary public interest authority that it can exercise to apply additional or more stringent criteria for the continued listing of the Company's common shares, or suspend or delist securities. As noted above, the Company sought and received approval at its Annual General and Special Meeting of Shareholders to complete, at the Board of Directors' discretion, a reverse stock split for purposes of regaining compliance with the minimum bid price requirement. The Company believes that having the advance approval of its shareholders to effect a reverse stock split provides strong support for its request for an additional 180-day extension and therefore increases the likelihood that the Panel will grant the requested extension; however, there can be no assurance that the Company's appeal before the Panel will be successful.

The Company is also listed on the Toronto Stock Exchange (the "TSX") and the Company's noncompliance with the Nasdaq minimum bid price requirement does not affect the Company's compliance status with the TSX.

About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe . For more information, visit: www.neovasc.com.

This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities laws regarding the Company's strategy and expectations regarding the process for seeking an additional extension of time to regain compliance with Nasdaq's minimum bid price requirement, whether or when the Company will complete a reverse stock split, and the Company's ability to remain listed on the Nasdaq Capital Market. Words and phrases such as "intends", "continue", "believe", "may", "could", "expect" and "will", and similar words or expressions, are intended to identify these forward-looking statements. Forward-looking statements are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the circumstances. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statements, including, without limitation, the substantial doubt about the Company's ability to continue as a going concern; risks relating to the warrants (the "Warrants") and senior secured convertible notes (the "Notes") issued pursuant to the November 2017 underwritten public offering and concurrent private placement (together, the "2017 Financings"), resulting in significant dilution to the Company's shareholders; risks relating to the Company's need for significant additional future capital and the Company's ability to raise additional funding; risks relating to cashless exercise and adjustment provisions in the Warrants and Notes issued pursuant to the 2017 Financings, which could make it more difficult and expensive for the Company to raise additional capital in the future and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company; risks relating to the exercise of Warrants or conversion of Notes issued pursuant to the 2017 Financings, which may encourage short sales by third parties; risks relating to the possibility that the Company's common shares may be delisted from the Nasdaq Capital Market or the Toronto Stock Exchange, which could affect their market price and liquidity; risks relating to the Company's common share price being volatile; risks relating to the influence of significant shareholders of the Company over the Company's business operations and share price; risks relating to the Company's significant indebtedness, and its effect on the Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual property rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual property rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry, including the risk that one or more of the Company's competitors may develop more effective or more affordable products; risks relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of participants in the medical device industry, including frequent government investigations into marketing and other business practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products; health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter into fundamental transactions as defined in the Series C warrants issued pursuant to the 2017 Financings; anti-takeover provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to the Company's shareholders; and risks relating to conflicts of interests among the Company's officers and directors as a result of their involvement with other issuers. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section of the Company's Annual Report on Form 20-F and in Management's Discussion and Analysis for the quarter ended March 31, 2018 (copies of which may be obtained at www.sedar.com or www.sec.gov). In particular, the Company notes that shareholder approval of the reverse stock split does not necessarily guarantee that the Nasdaq Hearings Panel will grant it an extension to regain compliance with the US$1.00 minimum bid price requirement or that, if granted, such extension will be for the additional 180-days requested by the Company. In addition to the specified criteria for continued listing, the Nasdaq also has broad discretionary public interest authority that it can exercise to apply additional or more stringent criteria for the continued listing of the Company's common shares, or suspend or delist securities even if the securities meet all enumerated criteria for continued listing on the Nasdaq. There can be no assurance that the Nasdaq will not exercise such discretionary authority. In addition, even if the Company is granted an extension by the Panel, there is no assurance that the Company will be able to regain compliance with the minimum bid price requirement prior to the expiry of any extension, or if it does, that the Company will be able to maintain such compliance as a result of the risks and uncertainties described above. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with securities regulators, whether as a result of new information, future events or otherwise, except as required by law.

Cision

View original content:http://www.prnewswire.com/news-releases/neovasc-receives-expected-delisting-determination-from-nasdaq-staff-and-will-request-nasdaq-hearing-300677401.html

SOURCE Neovasc Inc.


View original content: http://www.newswire.ca/en/releases/archive/July2018/09/c4702.html

  • Elon Musk’s 150mph 'Loop' tunnel system to open in December
    Business
    The Telegraph

    Elon Musk’s 150mph 'Loop' tunnel system to open in December

    Taking to Twitter, the billionaire SpaceX founder said his underground tunnel for the project "is almost done" and will be ready on December 10. The tunnel, which is being built by Musk's Boring Company, will contain autonomous electric skates capable of transporting cars and people at speeds of up to  125-150mph. The Boring Company's website says the tunnel runs from SpaceX's parking lot east of Crenshaw Boulevard and south of 120th Street, then turns west under 120th Street, and remains underground along 120th Street for 2 miles.

  • Better Buy: Aurora Cannabis Inc. vs. Canopy Growth Corporation
    Business
    Motley Fool

    Better Buy: Aurora Cannabis Inc. vs. Canopy Growth Corporation

    Canadian marijuana producers have entered a new era. After several years of supplying medical marijuana nationwide, they have begun moving into Canada's recreational marijuana market, which opened on Oct. 17. Canopy's share price has soared three times higher than Aurora's has.

  • Don’t cheat yourself with the 4% rule
    Business
    MarketWatch

    Don’t cheat yourself with the 4% rule

    If you’re planning for retirement, you’re probably thinking about how much you’ll need, how long the money will last, and how much you can safely take out each year. You recognize that in retirement there will be a balancing act between spending on current needs while also preserving enough for your later years. Instead, all-too-often, retirees use simplified rules of thumb to determine how much to take out each year.

  • Can AMD Stock Go on a Bull Run Once Again?
    Business
    Motley Fool

    Can AMD Stock Go on a Bull Run Once Again?

    Advanced Micro Devices (NASDAQ: AMD) shares have fallen off a cliff over the past month, as investors are probably concerned about whether it can sustain its rally in the face of a fading tailwind and rising competition. The chipmaker has minted a lot of money thanks to cryptocurrency mining, but that catalyst is fizzling out and rival NVIDIA (NASDAQ: NVDA) has launched a new generation of graphics chips to reclaim its lost market share. AMD blames weak GPU sales to the cryptocurrency market for this slowdown, but recent developments indicate that it could easily surpass the low-balled guidance.

  • Business
    Benzinga

    Barron's Picks And Pans: Alibaba, Citizens Financial, FAANG Stocks And More

    This weekend's Barron's cover story shows why emerging markets may be ready to rebound. Other featured articles examine why stocks will rally in 2019 and how to play preferred stock as yields rise. Also: the prospects for Chinese internet giants and

  • Better Buy: Ford Motor Company vs. General Motors
    Business
    Motley Fool

    Better Buy: Ford Motor Company vs. General Motors

    Both Ford Motor Company (NYSE: F) and General Motors (NYSE: GM) have been investor favorites in the not-too-distant past, and both pay good dividends. Ford has a slew of new products on the way, starting with a brand-new Ranger pickup early next year. Ford and GM have both had a rough year in the stock market.

  • Democrats Hold a 9-Point Lead in Midterms. But Trump's Job Rating Is at an All-Time High
    Politics
    Fortune

    Democrats Hold a 9-Point Lead in Midterms. But Trump's Job Rating Is at an All-Time High

    Democrats hold a nine-point lead going into the midterm elections Nov. 6, but President Donald Trump’s job rating is at an all-time high, according to a new NBC News/Wall Street Journal poll. The Democrats’ nine-point lead is among likely voters, who prefer Democratic Congressional candidates over Republicans by that margin. Trump’s job rating among registered voters between Oct. 14 and 17 was at 47% approve to 49% disapprove, compared to 44% approve and 52% disapprove a month earlier.

  • Say Goodbye to Amazon's Blockbuster Revenue Growth
    Business
    Motley Fool

    Say Goodbye to Amazon's Blockbuster Revenue Growth

    Throughout its history, Amazon (NASDAQ: AMZN) has possessed a certain ingenuity in finding new ways to grow. Just when the company seems to be maturing in one sector, it finds a new one to jump into. Since the company's early history, its quarterly revenue growth has cycled between 15% and 50%, depending on where it is in the growth cycles in the above businesses.

  • This Warren Buffett Stock Is Dirt Cheap Right Now
    Business
    Motley Fool

    This Warren Buffett Stock Is Dirt Cheap Right Now

    Warren Buffett has amassed a large portfolio of bank stocks for Berkshire Hathaway (NYSE: BRK-A) (NYSE: BRK-B) with major holdings in Bank of America (NYSE: BAC), Wells Fargo (NYSE: WFC), and American Express (NYSE: AXP), just to name a few of the most well-known and largest investments. Synchrony is a major issuer of store-branded credit cards and also operates a rapidly growing online banking platform.

  • Saudi Arabia's King and Crown Prince Call Slain Journalist Jamal Khashoggi's Son
    World
    Meredith Videos

    Saudi Arabia's King and Crown Prince Call Slain Journalist Jamal Khashoggi's Son

    Saudi Crown Prince Mohammed bin Salman called the son of Jamal Khashoggi, the kingdom announced early Monday, to express condolences for the death of the journalist killed at the Saudi Consulate.

  • 3 Dividend Stocks That Pay You More Than Coca-Cola Does
    Business
    Motley Fool

    3 Dividend Stocks That Pay You More Than Coca-Cola Does

    With a better than 50-year history of paying dividends, Coca-Cola (NYSE: KO) is seen as an icon of stable, strong, secure payouts. Although Coke and its dividend are not in trouble, there are better investments to be found. Three stocks that these Motley Fool contributors particularly like are Dominion Energy (NYSE: D), AbbVie (NYSE: ABBV), and MGM Growth Properties (NYSE: MGP).

  • Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?
    Business
    Motley Fool

    Which Canadian Marijuana Stock Will Enjoy a Bigger Bump From Its NYSE Listing -- Aphria or Aurora?

    Maybe Wall Street should be called "Weed Street." Big Canadian marijuana grower Canopy Growth listed its stock on the New York Stock Exchange (NYSE) earlier this year. Aurora Cannabis (NASDAQOTH: ACBFF) begins trading on the NYSE on Tuesday, Oct. 23. Aphria (NASDAQOTH: APHQF) filed last week to list its stock on the NYSE.

  • Amazon earnings, GDP report — What you need to know for the week ahead
    Finance
    Yahoo Finance

    Amazon earnings, GDP report — What you need to know for the week ahead

    The stock market is looking for direction. This past week, markets had big swings up and down before closing the week mostly unchanged, with the tech-heavy Nasdaq dropping fractionally while the S&P 500 closed right at its 200-day moving average, a level that has been of particular focus for markets over the last several trading sessions. “The volatility in equity markets continued this week as a long list of domestic and global concerns overshadowed upbeat US economic data and a positive start to Q3 earnings season,” said Gregory Daco, head of U.S. economics at Oxford Economics.

  • A Reduced Payout Could Be Coming for These 3 High-Yield Dividend Stocks
    Business
    Motley Fool

    A Reduced Payout Could Be Coming for These 3 High-Yield Dividend Stocks

    The bull market has been churning higher for nearly 10 years now as the S&P 500 has more than quadrupled since the market bottom in 2009. Investors in some high-yield dividend stocks may be worried about a payout cut, especially with rising interest rates making bonds more appealing. Let's take a closer look at three high-yield dividend stocks that could see a reduced payout.

  • Here's Which Marijuana Stocks Investors Are Betting Against the Most
    Business
    Motley Fool

    Here's Which Marijuana Stocks Investors Are Betting Against the Most

    Canada's recreational marijuana market is now open for business. Some are confident enough that certain marijuana stocks will fall that they're putting a lot of money on the line expecting that's exactly what will happen. The marijuana grower's low stock float and wild swings over the last month have received a lot of attention.

  • This Midstream Oil & Gas Stock Is Still a Steal
    Business
    Motley Fool

    This Midstream Oil & Gas Stock Is Still a Steal

    The midstream sector is out of favor today, with the Alerian MLP ETF still off roughly 45% from its mid-2014 highs. Midstream companies own the assets that move oil, natural gas, and related products around the country. Investors were pretty excited about this space a few years back, pushing the prices of midstream companies higher and their yields lower.

  • 3 Reasons Alibaba Stock Could Rise
    Business
    Motley Fool

    3 Reasons Alibaba Stock Could Rise

    After reaching an all-time high of $211.70 in June, Alibaba (NYSE: BABA) shares have shed nearly a third of their value as fears of an escalating trade war between China and the U.S. rattled investors. China's e-commerce market will grow to $1.8 trillion by 2022, according to Forrester, up from $1.1 trillion this year. With only 38% of China's 1.4 billion people currently making purchases online, this massive market is set to grow briskly for many years to come.

  • The Pre-Markets Rundown: October 22, 2018
    Business
    CNBC Videos

    The Pre-Markets Rundown: October 22, 2018

    CNBC brings you fast, accurate, and actionable business news and market updates.

  • 3 Energy Stocks You Can Buy and Hold for the Next Decade
    Business
    Motley Fool

    3 Energy Stocks You Can Buy and Hold for the Next Decade

    North America needs to build $23 billion of new natural gas-related infrastructure annually through 2035, according to a recent report. Three of the best positioned to capture this growth are Kinder Morgan (NYSE: KMI), Williams Companies (NYSE: WMB), and TransCanada (NYSE: TRP), making them great stocks to buy and hold in the coming decade. Kinder Morgan is already the largest natural gas pipeline company in North America, operating roughly 70,000 miles of pipeline.

  • Religious Extremists Got Their Justice. Now They're Going To Strip LGBTQ Rights.
    Politics
    HuffPost Opinion

    Religious Extremists Got Their Justice. Now They're Going To Strip LGBTQ Rights.

    While much of the country was in an uproar over the nomination (and confirmation) of Brett Kavanaugh to the U.S. Supreme Court, anti-LGBTQ religious extremists in Texas filed a federal lawsuit against the city of Austin targeting its anti-discrimination ordinance protecting LGBTQ people, claiming it infringes on their religious liberty. Like many municipalities and less than half of U.S. states, Austin protects gay, lesbian, bisexual and transgender people broadly from discrimination in housing, employment and public accommodations.

  • Business
    Benzinga

    Bulls & Bears Of The Week: Apple, Disney, Ford, Home Depot And More

    Benzinga has featured looks at many investor favorite stocks over the past week. Bullish calls included leaders in entertainment, tobacco and video games. Bearish calls included a Detroit automaker and big box retailer. Last week began with a mystery

  • 3 Warren Buffett Stocks Worth Buying Now
    Business
    Motley Fool

    3 Warren Buffett Stocks Worth Buying Now

    Known as the Oracle of Omaha, Warren Buffett has collected both an incredible investment record and a deservedly vast following among investors of all types. Every move he makes is scrutinized in the hope of gleaning  wisdom from his investment choices.

  • Suze Orman has a killer question for your retirement
    Business
    MarketWatch

    Suze Orman has a killer question for your retirement

    Suze Orman is one of those singular personalities in the financial business who seems to be right on the pulse of everyone she meets. She’s written books, starred in her own television show and made innumerable appearances in person. Like Oprah

  • Get Ready for Intel Earnings
    Business
    Motley Fool

    Get Ready for Intel Earnings

    Ahead of Intel's earnings release, it's worth recapping what the company told investors to expect and what the analyst community is expecting. When Intel released its second-quarter financial results on July 26, it provided detailed financial guidance for the subsequent quarter, as well as for the full year. The company told investors to expect third-quarter revenue of between $17.6 billion and $18.6 billion and operating margin of "approximately" 32.5%.

  • The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs
    News
    MarketWatch

    The ‘smart money’ says it’s time to buy the Chinese internet giants and the U.S. FAANGs

    When the media and investors turn negative on stocks but the “smart money” is bullish, it’s a good time to think about buying. After all, exactly what is the smart money, and how do you know? Lately, several fund managers who pass this test have been pounding the table on Chinese internet names.